Enveric Biosciences IncENVB
Price$1.46

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$8.8MTTM through 31 Dec 2025
Free Cash Flow -$8.1MTTM through 31 Dec 2025

Margins

Current

Returns

-209.9%ROE
-172.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Net Debt-$4.3Mnet cash position
Cash & Equivalents$4.3M

Quality Metrics

Earnings-Beat Rate100.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Neuroplastogenic Therapeutics$0
View details

Advancing EB-003 toward IND filing and planned first-in-human clinical trials.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.